Sphingosine kinase inhibitor prodrugs
US8685936B2 · kind B2 · utility
1Cited by
1References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2010 |
| Grant date | Apr 1, 2014 |
| Priority date | — |
| Expiry date | Jul 28, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.